Literature DB >> 21606088

In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis.

Juan Antonio Moreno1, Almudena Ortega-Gómez, Sandrine Delbosc, Nathalie Beaufort, Emmanuel Sorbets, Liliane Louedec, Marina Esposito-Farèse, Florence Tubach, Antonino Nicoletti, Philippe Gabriel Steg, Jean-Baptiste Michel, Laurent Feldman, Olivier Meilhac.   

Abstract

AIMS: CD163 is a macrophage receptor for haemoglobin-haptoglobin (Hb-Hp) complexes, responsible for the clearance of haemoglobin. We hypothesized that production of soluble CD163 (sCD163) may be due to proleolytic shedding of membrane CD163 by neutrophil elastase, reported to be increased in culprit atherosclerotic plaques. We analysed the relationship between CD163 solubilization and elastase in vitro, in macrophage culture, ex vivo in human atherosclerotic plaque samples, and in vivo, in plasma of patients with coronary artery disease. METHODS AND
RESULTS: Neutrophil elastase was shown to enhance CD163 shedding and to decrease the uptake of Hb-Hp complexes by cultured macrophages. In addition, cultured carotid endarterectomy samples showing features of intraplaque haemorrhage released more sCD163 and elastase/α1-antitrypsin (α1-AT) complexes than non-haemorrhagic plaques (n= 44). Plasma levels of sCD163 and neutrophil elastase (complexed with α1-AT) were measured in patients with an acute coronary syndrome (ACS, n= 42), stable angina pectoris (SAP, n= 28), or normal coronary angiograms without subclinical atherosclerosis (n= 21). Acute coronary syndrome patients had higher sCD163 and elastase/α1-AT complexes plasma concentrations than subjects without coronary atherosclerosis. Circulating sCD163 and elastase/α1-AT complexes were positively correlated in patients with ACS (r = 0.56, P< 0.0002) and SAP (r = 0.62, P< 0.0005).
CONCLUSION: Our results suggest that neutrophil elastase promotes CD163 shedding, resulting in a decreased clearance of Hb by macrophages, which may favour plaque destabilization. This may be reflected by increased plasma levels of sCD163 and elastase/α1-AT complexes which are positively correlated in patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606088     DOI: 10.1093/eurheartj/ehr123

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

1.  Identification and Validation of Candidate Gene Module Along With Immune Cells Infiltration Patterns in Atherosclerosis Progression to Plaque Rupture via Transcriptome Analysis.

Authors:  Jing Xu; Cheng Chen; Yuejin Yang
Journal:  Front Cardiovasc Med       Date:  2022-06-22

2.  HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P.

Authors:  Florin Tuluc; John Meshki; Sergei Spitsin; Steven D Douglas
Journal:  J Leukoc Biol       Date:  2014-02-27       Impact factor: 4.962

3.  Ex vivo culture of human atherosclerotic plaques: A model to study immune cells in atherogenesis.

Authors:  Anna Lebedeva; Daria Vorobyeva; Murad Vagida; Oxana Ivanova; Eugeny Felker; Wendy Fitzgerald; Natalya Danilova; Vladimir Gontarenko; Alexander Shpektor; Elena Vasilieva; Leonid Margolis
Journal:  Atherosclerosis       Date:  2017-10-07       Impact factor: 5.162

4.  CD163-Macrophages Are Involved in Rhabdomyolysis-Induced Kidney Injury and May Be Detected by MRI with Targeted Gold-Coated Iron Oxide Nanoparticles.

Authors:  Alfonso Rubio-Navarro; Mónica Carril; Daniel Padro; Melanie Guerrero-Hue; Carlos Tarín; Rafael Samaniego; Pablo Cannata; Ainhoa Cano; Juan Manuel Amaro Villalobos; Ángel Manuel Sevillano; Claudia Yuste; Eduardo Gutiérrez; Manuel Praga; Jesús Egido; Juan Antonio Moreno
Journal:  Theranostics       Date:  2016-04-21       Impact factor: 11.556

5.  Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.

Authors:  Alison Castley; Leah Williams; Ian James; George Guelfi; Cassandra Berry; David Nolan
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

6.  Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.

Authors:  Claudia Mascia; Serena Vita; Paola Zuccalà; Raffaella Marocco; Tiziana Tieghi; Stefano Savinelli; Raffaella Rossi; Marco Iannetta; Irene Pozzetto; Caterina Furlan; Fabio Mengoni; Claudio Maria Mastroianni; Vincenzo Vullo; Miriam Lichtner
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

Review 7.  Clinical significance of sCD163 and its possible role in asthma (Review).

Authors:  Yue Zhi; Peng Gao; Xiuqin Xin; Wei Li; Lei Ji; Lin Zhang; Xueyang Zhang; Jie Zhang
Journal:  Mol Med Rep       Date:  2017-03-24       Impact factor: 2.952

Review 8.  The role of monocytosis and neutrophilia in atherosclerosis.

Authors:  Dimitry A Chistiakov; Andrey V Grechko; Veronika A Myasoedova; Alexandra A Melnichenko; Alexander N Orekhov
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

9.  Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Authors:  Luis M Beltrán; Rocío Muñoz Hernández; Rebeca S de Pablo Bernal; José S García Morillo; Jesús Egido; Manuel Leal Noval; Sara Ferrando-Martinez; Luis M Blanco-Colio; Miguel Genebat; José R Villar; Rafael Moreno-Luna; Juan Antonio Moreno
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

10.  The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes.

Authors:  Reina Kawarabayashi; Koka Motoyama; Miyuki Nakamura; Yuko Yamazaki; Tomoaki Morioka; Katsuhito Mori; Shinya Fukumoto; Yasuo Imanishi; Atsushi Shioi; Tetsuo Shoji; Masanori Emoto; Masaaki Inaba
Journal:  J Diabetes Res       Date:  2017-12-28       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.